No Data
No Data
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Jafron Biomedical (300529.SZ): Its new product, blood dialysis concentrate, from Hubei Jafron has obtained the third-class medical instrument registration certificate.
Jafron Biomedical (300529.SZ) announced on August 19th that its wholly-owned subsidiary, Hubei Jafron Biomedical Technology Co., Ltd. (hereafter referred to as "Hubei Jafron"), recently received the "Medical Instruments Registration Certificate" issued by the National Medical Products Administration for its new product, hemodialysis concentrate. The new product raises the limit indicators for microorganisms and endotoxins to be consistent with the standards for ultrapure dialysis fluid, representing an important layout for the company in the field of blood purification treatment.
CEO Fan Dong, Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Largest Shareholder Sees Value of Holdings Go Down 3.2% After Recent Drop
Jafron Biomedical: Summary of Half-Year Report in 2024.
Jafron Biomedical: Half-year report for the year 2024.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Jafron BiomedicalLtd (SZSE:300529) Stock Falls a Further 6.7% in Past Week
No Data